---
title: How CDMOs and CROs Sell to Biotech Companies | Torke
url: https://torke.tech/industries/pharma-and-life-sciences
description: Why biotech deals stall at the supplier audit, who signs, which dated signals open an account, and how CDMOs, CROs and lab tool firms get qualified leads.
---

# From a passed audit to a signed program

You sell development or manufacturing services, clinical research services or laboratory tools to biotech and pharma companies, often to a program that has just raised money or reached a new trial phase. The companies that fit are a finite list, and most of your pipeline sits between a good scientific conversation and a supplier qualification that nobody started.

Diagram: Dated signals in Pharma & Life Sciences

In Pharma & Life Sciences, three dated signals open a target account for outreach: Funding round closed, Trial registered, Head of CMC hired.

## Who this page is for

- CDMOs selling development and manufacturing services to biotech companies
- CROs selling clinical research services to programs entering a new trial phase
- Laboratory tools companies selling to biotech and pharma teams

Usual starting point: [Demand](https://torke.tech/service#practices)

## How do you increase sales for a CDMO, CRO or lab tools company?

Follow dated events at a short list of biotech accounts at the right stage, such as a financing round or a new trial registration, and reach the head of CMC and quality early. Quality assurance will audit you and the contract takes months, so bring quality and procurement in before the program lead asks for a quote.

## What do the numbers say about Pharma & Life Sciences?

Each figure links to the page it comes from, so you can check it before you repeat it.

| What the evidence says | Source |
|---|---|
| The EU GMP Guide requires a written contract between the contract giver and the contract acceptor that sets out each party's duties. | EU GMP Guide, Chapter 7 (2012) |
| Practitioner guidance advises starting tech transfer 12 to 18 months before the first GMP batch is needed. | Drug Discovery News (2026) |
| Swiss biotech companies raised more than CHF 2.5 billion in 2024, including a record CHF 833 million raised by private companies. | EY Switzerland, Swiss Biotech Report 2025 (5 May 2025) |
| Chemistry, pharma and life sciences made up just over 52% of Swiss exports in 2024, CHF 149.08 billion. | scienceindustries (30 January 2025) |

[](https://www.gmp-navigator.com/files/guidemgr/vol4-chap7_2012-06_en.pdf) [](https://www.drugdiscoverynews.com/negotiating-tech-transfer-and-quality-agreements-with-your-cd) [](https://www.ey.com/en_ch/newsroom/2025/05/swiss-biotech-report-2025-highlights-sectors-continui) [](https://scienceindustries.ch/en/article/43992/foreign-trade-figures-for-2024)

## Why does the usual approach stall in Pharma & Life Sciences?

A scientist or program lead can want your service, but outsourcing a regulated activity requires more than their agreement. The EU GMP Guide requires a written contract that sets out each party's duties, makes the contract giver responsible for assessing the competence of the contract acceptor, and expects the contract to permit audits of the outsourced work. In practice, quality assurance has to audit you, procurement and legal have to agree a contract and a quality agreement, and practitioner guidance advises starting tech transfer 12 to 18 months before the first GMP batch is needed. When those steps start late, the program goes to whoever is already qualified.

Volume marketing reaches researchers who are curious and rarely the program lead with a budget and a date. Your accounts are the companies at the right stage in the right modality, and the moment they need you shows in public events such as a financing or a trial registration, so ads optimised on clicks spend most of the budget outside that list.

If you are a large company with your own account teams and medical marketing, this page does not describe you, because those programs are run in-house. If your list is very small and a year can pass between first contact and a contract, Torke works with you on a subscription rather than per lead, and the Diagnostic says plainly whether the work is worth starting.

## Where does pipeline break in Pharma & Life Sciences?

We look at five stages in the Diagnostic, because each fails for a different reason. The rows show the failure we look for first at each stage and what changes once Torke fixes it, in the order a deal meets them.

### Discovery

Where it breaks

Curious researchers find the content, while the program lead with a budget and a date never sees material written for their stage

What changes once it is fixed

Torke's Visibility practice builds the pages program leads and quality read before sales, and checks that AI assistants describe the service correctly

### Timing

Where it breaks

A biotech that closed a round or registered a trial picks suppliers in the following months, and a vendor who hears late meets a set shortlist

What changes once it is fixed

Account signals bring financings, trial registrations and hiring at your target accounts each morning, from newsrooms, job boards and regulator feeds

### Evaluation

Where it breaks

Quality assurance audits you before you can be used, and a claim your own quality team would not sign reads as a warning to auditors

What changes once it is fixed

Campaigns on approved claims checks every capacity, timeline and regulatory statement against the facts your quality team approved before export

### Qualification

Where it breaks

Requests from students, academics and companies years from the clinic take the same sales time as a funded program with a date

What changes once it is fixed

Inbound response qualifies every request and routes it by segment and language, and can run in draft mode so your team checks each answer

### Handover

Where it breaks

A program lead's interest sits in the CRM as pipeline while no audit date exists, and the decision drifts toward a supplier already qualified

What changes once it is fixed

Torke's Revenue operations practice sets lifecycle stages so a program waiting for its audit is counted apart from one with a quality agreement

## Who is in the buying group?

One person rarely decides alone, so a lead from the wrong role moves nothing. These are the roles we map at every account on your list.

### Who signs

The head of CMC, development or clinical operations, with the CEO or CFO approving larger contracts at a smaller biotech.

### Who evaluates

The program lead and the scientists who will use the work, the CMC or clinical operations team, and quality assurance, which audits you before you can be used.

### Who can block

Quality assurance when the audit finds gaps, procurement and legal through the contract and the quality agreement, and the investors who decide when the next phase is funded.

## Which signals open an account in Pharma & Life Sciences?

Each signal is a dated, public event a sceptical buyer could check in thirty seconds. Market-wide news can change an account's conditions, and we never write it up as something that company did.

| Signal | What it changes inside the account |
|---|---|
| A financing round with a stated use of funds | Money for a defined program now exists, and suppliers for its next stage will be chosen in the following months |
| A new trial appears in the EU Clinical Trials Information System | The program has a dated plan, and the services that phase needs are being bought |
| Trial results or a regulatory designation are announced | The next phase needs more material and more sites, and often suppliers the company has not used before |
| Hiring for a head of CMC, quality or clinical operations | Someone has been given the job of building the supplier base and is choosing it now |
| A licensing deal or partnership is announced | A partner's timeline now applies, and capacity has to be secured to meet it |

## What does a qualified lead look like here?

The head of CMC at a biotech company on your agreed list replies that their lead program starts a phase 2 trial next year, that they need a second manufacturing site qualified before then, and asks when your team could host an audit. The basis for contacting them in their country is recorded, and the account is not an open opportunity in your CRM. That reply, with the financing announcement it answered, is a qualified lead.

A lead counts only when all five facts are recorded, and you have five business days to reject it with a reason. The [Torke Service page](https://torke.tech/service#qualified) explains each fact.

**Fact one**

A named person in the buying group

**Fact two**

At an account you agreed to in writing

**Fact three**

A need or timing in their own words

**Fact four**

A lawful basis for contact

**Fact five**

Not already open in your CRM

## Where should you start?

Demand is the practice the Diagnostic most often points to for life sciences service and tools companies, because qualifying a supplier follows a dated event at the account, such as a financing or a trial registration.

Every engagement opens with the Diagnostic, two to three weeks that end on one of four decisions: stop, fix one barrier, run one practice, or expand later.

Usual first step for Pharma & Life Sciences

[Demand](https://torke.tech/service#practices)

The practice the Diagnostic most often points to here, run month by month once it does.

[Get in touch](#get-in-touch)

## How do Torke Service and Torke Engine help?

The same engines run in both, so you can begin with one and move to the other without starting over.

### Torke Service, we run it

For example, a cell therapy CDMO whose sales team talks mostly to scientists learns in the Diagnostic that its won deals started with a head of CMC soon after a financing. Torke runs Demand against the biotech companies on the agreed list, watches financings and trial registrations, and passes each lead with its evidence, while your team keeps the audit, the technical work and the contract.

[How Torke Service works](https://torke.tech/service)

### Torke Engine, your team runs it

Account signals and first-touch outreach matter most here. A financing or a trial registration gives a precise reason to write, and the first email has to rest on what the company itself published, because its readers check claims for a living.

For example, a marketer asks the assistant to find the biotech companies on the list that announced a financing or registered a new trial this month and to draft a first email to each head of CMC. The assistant returns the ranked accounts with each dated event and its source, and drafts where every sentence traces to that event and anything inferred about their needs is written as a question, for a person to review and send.

[How Torke Engine works](https://torke.tech/engine)

## What can you expect?

You can stop after any stage and keep what it produced.

### An honest answer on fit

The Diagnostic can end on stop, and in an industry with long regulated cycles that is a real outcome, stated in writing with the reason.

### First leads with their evidence

Each lead names a person in the buying group, their need or timing in their own words and the lawful basis for contact, and you have five business days to reject it.

### Small results called small

The monthly read reports accounts moved into conversations and coverage of your list, and results too small to judge are reported as too small to judge rather than rounded up.

## What do teams in Pharma & Life Sciences ask about Torke?

Each answer stands on its own, so you can forward one to a colleague, and an assistant asked the same question can quote it as it is.

### Where should a CDMO or CRO start with Torke?

A CDMO, CRO or lab tools company starts with Torke's Diagnostic, which looks at the programs that went to another supplier and at whether the account list follows each company's stage and modality. It most often points to the Demand practice, because a biotech qualifies a supplier after a dated event such as a financing or a trial registration, and the work is to be in the conversation with quality and the program lead when it happens.

### Why does a biotech take months to sign with a new CDMO?

Under the EU GMP Guide, outsourcing a regulated activity needs a written contract and lets the biotech audit the work, so its quality assurance audits the CDMO while procurement and legal agree a contract and a quality agreement. Practitioner guidance advises starting tech transfer 12 to 18 months before the first GMP batch is needed, which is why Torke's Demand practice brings quality and procurement at the account into the conversation early.

### How can a CDMO reach biotech companies right after a financing round?

Torke Engine's Account signals module brings dated public events at a CDMO's target accounts each morning, such as a financing or a new trial in the EU Clinical Trials Information System, ranked with the opening line the strongest event justifies. First-touch outreach then drafts an email to the head of CMC where every sentence traces to that event, and a person reviews and sends it.

### How long is the sales cycle for life sciences companies selling to biotech companies?

For outsourced manufacturing it often runs past a year, because the EU GMP Guide requires a written contract and lets the biotech audit the supplier, and practitioner guidance advises starting tech transfer 12 to 18 months before the first GMP batch is needed.

### How can a CDMO generate leads without wasting ad budget?

Work a named list of biotech companies at the right stage and modality, watch financings and trial registrations at those accounts, and write to the program lead with the dated event as the reason.

## Read next on Pharma & Life Sciences

Articles that go deeper on what stalls deals in this market, and the industries whose buyers behave the same way.

### Why per-lead pricing starts as a subscription

Nobody knows on day one how many qualified leads an account list can produce, so a fair price per lead has to be measured before it is charged.

[Read the article, 5 minutes](https://torke.tech/blog/why-per-lead-pricing-starts-as-a-subscription)

### What counts as a qualified lead

Most arguments between marketing and sales about pipeline are arguments about a definition nobody wrote down. Five recorded facts settle them before they start.

[Read the article, 5 minutes](https://torke.tech/blog/what-counts-as-a-qualified-lead)

### The week something changed

In a category with no search volume, the only reliable opening is reaching an account inside the window a dated, public event created.

[Read the article, 4 minutes](https://torke.tech/blog/the-week-something-changed)

### Medtech

Surgical systems, implants, diagnostic devices and wearables sold to hospitals, clinics and labs, where a clinician champions the device and a committee or tender decides.

[How we work in Medtech](https://torke.tech/industries/medtech)

### Digital Health

Hospital software, telemedicine and health data platforms sold to hospitals, clinic groups and insurers, where a clinician champions and IT, data protection and procurement decide.

[How we work in Digital Health](https://torke.tech/industries/digital-health)

### Advanced Materials & Chemicals

Coatings, nanomaterials and specialty chemicals sold to manufacturers in automotive, electronics, packaging and medical devices, where a material is specified before it is bought.

[How we work in Advanced Materials & Chemicals](https://torke.tech/industries/advanced-materials-and-chemicals)

## Other industries

[

Fintech & Crypto

- ](https://torke.tech/industries/fintech-and-crypto)

[

Robotics & Industrial Automation

- ](https://torke.tech/industries/robotics-and-industrial-automation)

[

Semiconductors & Electronics

- ](https://torke.tech/industries/semiconductors-and-electronics)

[

Medtech

- ](https://torke.tech/industries/medtech)

[

Precision Engineering & Machinery

- ](https://torke.tech/industries/precision-engineering-and-machinery)

[

Cleantech & Energy

- ](https://torke.tech/industries/cleantech-and-energy)

[

Cybersecurity

- ](https://torke.tech/industries/cybersecurity)

[

Wealth & Asset Management

- ](https://torke.tech/industries/wealth-and-asset-management)

[

Advanced Materials & Chemicals

- ](https://torke.tech/industries/advanced-materials-and-chemicals)

[

Software & AI

- ](https://torke.tech/industries/software-and-ai)

[

Aerospace & Space

- ](https://torke.tech/industries/aerospace-and-space)

[

Insurance & Insurtech

- ](https://torke.tech/industries/insurance-and-insurtech)

[

Real Estate & Proptech

- ](https://torke.tech/industries/real-estate-and-proptech)

[

Legal & Compliance Tech

- ](https://torke.tech/industries/legal-and-compliance-tech)

[

Digital Health

- ](https://torke.tech/industries/digital-health)

[

Finance & Banking

- ](https://torke.tech/industries/finance-and-banking)

[

Agritech & Food Tech

- ](https://torke.tech/industries/agritech-and-food-tech)

[

Cloud & Data Infrastructure

- ](https://torke.tech/industries/cloud-and-data-infrastructure)

[

Logistics & Supply Chain

- ](https://torke.tech/industries/logistics-and-supply-chain)

[

Telecom & IoT

- ](https://torke.tech/industries/telecom-and-iot)

[

Mobility & Automotive

- ](https://torke.tech/industries/mobility-and-automotive)

[

Luxury & Watchmaking

- ](https://torke.tech/industries/luxury-and-watchmaking)

[

Construction & Building Tech

- ](https://torke.tech/industries/construction-and-building-tech)

[

Consulting & Professional Services

- ](https://torke.tech/industries/consulting-and-professional-services)

[All industries

- ](https://torke.tech/industries)